Dragomir, R.-D.; Mercioni, M.A.; Negru, Ș.; Popovici, D.; Săftescu, S.; Blidari, A.R.; Sas, I.
Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC). J. Pers. Med. 2025, 15, 39.
https://doi.org/10.3390/jpm15010039
AMA Style
Dragomir R-D, Mercioni MA, Negru Ș, Popovici D, Săftescu S, Blidari AR, Sas I.
Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC). Journal of Personalized Medicine. 2025; 15(1):39.
https://doi.org/10.3390/jpm15010039
Chicago/Turabian Style
Dragomir, Radu-Dumitru, Marina Adriana Mercioni, Șerban Negru, Dorel Popovici, Sorin Săftescu, Andiana Roxana Blidari, and Ioan Sas.
2025. "Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC)" Journal of Personalized Medicine 15, no. 1: 39.
https://doi.org/10.3390/jpm15010039
APA Style
Dragomir, R.-D., Mercioni, M. A., Negru, Ș., Popovici, D., Săftescu, S., Blidari, A. R., & Sas, I.
(2025). Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC). Journal of Personalized Medicine, 15(1), 39.
https://doi.org/10.3390/jpm15010039
